Cencora

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

Bleakley Financial Group LLC Has $5.35 Million Stake in Cencora, Inc ...

AI-generated analysis

πŸ“‰ Bleakley Financial Group LLC reduced its stake in Cencora by 39.4% in Q1, selling 11,082 shares while retaining 17,020 shares valued at $5.35 million.

πŸ“ˆ Multiple institutional investors increased their positions in Q4, with Accent Capital Management LLC raising its stake by 36.1% and JFS Wealth Advisors LLC growing its holding by 30.2%.

πŸ’° Cencora reported Q1 revenue of $78.36 billion, representing a 3.9% year-over-year increase despite missing the consensus EPS estimate by $0.07.

πŸ“Š Analyst consensus targets the stock at $367.75 with an average rating of 'Moderate Buy' based on reports from major firms like Wells Fargo and Bank of America.

πŸ”„ The company announced a new $2.00 billion stock repurchase plan authorized by its board to buy up to 3.9% of outstanding shares.

πŸ’΅ Shareholders received a quarterly dividend of $0.60 per share, resulting in an annualized yield of 0.8% and a payout ratio of 18.40%.

πŸ‘” Insider activity saw Director Lauren M. Tyler purchase 550 shares for approximately $148,626, increasing her direct ownership by 14.44%.

πŸ“‰ The stock currently trades at a P/E ratio of 23.17 with a market capitalization of $58.79 billion and a beta of 0.58.

πŸ₯ Cencora operates as a global leader in pharmaceutical distribution, managing wholesale drug supply chains and specialty pharmacy operations.

πŸ“‰ The stock recently opened at $302.16, trading above its 50-day moving average of $277.12 but below its 200-day average of $318.31.

Bullish Signals
  • Cencora initiated a $2.00 billion stock repurchase plan, signaling management's belief that the stock is undervalued and demonstrating commitment to returning capital to shareholders.
  • The company reported revenue growth of 3.9% year-over-year to $78.36 billion, indicating continued expansion in its core pharmaceutical distribution business despite missing earnings estimates.
  • Analyst consensus maintains a 'Moderate Buy' rating with an average price target of $367.75, suggesting potential upside from current levels as major banks like Wells Fargo and Bank of America maintain positive or neutral outlooks.
  • Director Lauren M. Tyler increased her direct ownership by 14.44% through a significant purchase of 550 shares, indicating insider confidence in the company's future prospects.
Risk Factors
  • Revenue of $78.36 billion fell short of the analyst consensus estimate of $81.09 billion, indicating a slight miss in top-line growth expectations for the quarter.
  • The stock trades below its 200-day simple moving average of $318.31, suggesting some near-term weakness or consolidation relative to longer-term trends.
  • The current ratio of 0.95 and quick ratio of 0.59 indicate liquidity constraints that could be a concern if cash flow dynamics deteriorate further in the coming quarters.
Full Analysis
Bleakley Financial Group LLC reduced its stake in Cencora, Inc. (NYSE:COR) by 39.4% in the first quarter, selling 11,082 shares to hold a remaining position of 17,020 shares valued at approximately $5.35 million. This move contrasts with several other institutional investors who increased their holdings in the fourth quarter, including JFS Wealth Advisors LLC, Apollon Wealth Management LLC, Accent Capital Management LLC, MCF Advisors LLC, and CYBER HORNET ETFs LLC, which collectively raised their stakes by varying percentages ranging from 0.5% to 36.1%. Analyst sentiment remains mixed but generally positive regarding the stock's valuation potential. Major financial institutions have issued updated price targets and ratings in recent months; for instance, Wells Fargo lowered its target to $331 with an 'overweight' rating, while Bank of America raised its target to $285 with a 'neutral' rating. The consensus average rating from eleven equities research analysts is currently a 'Moderate Buy' with a collective price target of $367.75. Financially, Cencora reported Q1 earnings of $4.75 per share, missing the consensus estimate of $4.82 by seven cents, while revenue reached $78.36 billion, slightly below the expected $81.09 billion but up 3.9% year-over-year. The company has initiated a $2.00 billion stock repurchase plan and recently paid a quarterly dividend of $0.60 per share, yielding 0.8%. Insider activity includes Director Lauren M. Tyler purchasing 550 shares for approximately $148,626 in late June. Cencora operates as a global healthcare services and pharmaceutical distribution company providing end-to-end solutions across the pharmaceutical supply chain. Its core activities include wholesale and specialty drug distribution, alongside logistics and cold-chain management for temperature-sensitive therapies. The firm also offers commercial and patient-focused services to pharmaceutical manufacturers and healthcare providers, maintaining a market capitalization of $58.79 billion.